You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)單抗生物類似藥HLX15一期臨床研究完成首例給藥
阿思達克 02-01 17:38
復宏漢霖(02696.HK)公布,旗下的達雷妥尤單抗生物類似藥HLX15(重組抗CD38全人單克隆抗體注射液),在中國男性健康受試者中開展的一期臨床研究,近日已完成首例受試者給藥。 HLX15是公司自主研發的達雷妥尤單抗生物類似藥,擬用於多發性骨髓瘤(MM)的治療,已於2015年11月獲美國食品藥品管理局(FDA)批准上市用於MM的治療,其皮下注射製劑於2020年5月獲批上市,並於2019年7月獲中國藥監局批准達雷妥尤單抗注射液上市,用於單藥治療複發和難治性MM成人患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account